Pharming (PHAR) Net Cash Flow (2019 - 2025)
Pharming's (PHAR) quarterly Net Cash Flow came in at $11.7 million in Q4 2025, up 125.44% YoY from $5.2 million in Q4 2024, and up 125.44% on a QoQ basis from -$46.0 million in Q4 2024.
Pharming (PHAR) Net Cash Flow (2019 - 2025) Analysis & Trends
Pharming (PHAR) has 7 years of Net Cash Flow data on file, last reported at $11.7 million in Q4 2025.
- Quarterly Net Cash Flow rose 125.44% year-over-year to $11.7 million in Q4 2025, while the trailing twelve-month figure through Jun 2026 was $11.7 million (up 135.1% YoY) and the FY2025 annual result came in at $82.5 million, up 1896.8% from the prior year.
- Net Cash Flow rose to $11.7 million in Q4 2025, from -$46.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $12.7 million in Q3 2024 to a low of -$147.7 million in Q4 2023.
- A 5-year average of -$32.1 million and a median of -$3.7 million in 2021 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 320.48% in 2022, down 24027.9% in 2022.
- Tracing PHAR's Net Cash Flow over 5 years: stood at -$11003.9 in 2021, then sank by 24027.9% to -$2.7 million in 2022, then plunged by 5464.18% to -$147.7 million in 2023, then surged by 68.86% to -$46.0 million in 2024, then soared by 125.44% to $11.7 million in 2025.
- The last three Net Cash Flow figures came in at $11.7 million (Q4 2025), -$46.0 million (Q4 2024), and $12.7 million (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.70 Mn |
| Dec 31, 2025 | 11.70 Mn |
| Dec 31, 2024 | -46.00 Mn |
| Dec 31, 2024 | -46.00 Mn |
| Sep 30, 2024 | 12.66 Mn |
| Sep 30, 2024 | 12.66 Mn |
| Dec 31, 2023 | -147.73 Mn |
| Dec 31, 2023 | -147.73 Mn |
| Sep 30, 2023 | -49.46 Mn |
| Sep 30, 2023 | -49.46 Mn |
| Jun 30, 2023 | -104.92 Mn |
| Jun 30, 2023 | -104.92 Mn |
| Dec 31, 2022 | -2.66 Mn |
| Dec 31, 2022 | -2.66 Mn |
| Sep 30, 2022 | 10.40 Mn |
| Sep 30, 2022 | 10.40 Mn |
| Dec 31, 2021 | -11,003.86 |
| Dec 31, 2021 | -11,003.86 |
| Sep 30, 2021 | -4.72 Mn |
| Sep 30, 2021 | -4.72 Mn |